The role of patient-based treatment planning in peptide receptor radionuclide therapy

2015 ◽  
Vol 43 (5) ◽  
pp. 871-880 ◽  
Author(s):  
Deni Hardiansyah ◽  
Christian Maass ◽  
Ali Asgar Attarwala ◽  
Berthold Müller ◽  
Peter Kletting ◽  
...  
Keyword(s):  
Treatment Planning ◽  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor

scholarly journals RADIONUCLIDE IMAGING AND THERAPY OF NEUROENDOCRINE TUMOURS

2015 ◽  
Vol 1 (2) ◽  
Author(s):  
Shaunak Navalkissoor ◽  
Gopinath Gnanasegaran
Keyword(s):  
Radionuclide Imaging ◽  
Radionuclide Therapy ◽  
Neuroendocrine Tumours ◽  
Somatostatin Receptor ◽  
Peptide Receptor Radionuclide Therapy ◽  
Clinical Results ◽  
It Use ◽  
Peptide Receptor ◽  
Mibg Therapy

The incidence and prevalence of neuroendocrine tumours (NETs) are on the rise. Although NETs are a heterogeneous group of tumours, they have some similar properties, for example, that they can concentrate neuroamines and tend to have a high degree of somatostatin receptor (SSR) expression. These mechanisms can be exploited and this article discusses the important role of radionculide imaging and radionculide therapy in the management of NETs based on these mechanisms. This article reviews the current literature and discusses the role of radionuclide imaging in NETs both in terms of SSR imaging and neuroamine (metaiodobenzylguanidine [MIBG]) imaging. We discuss state-of- the-art 68Ga-radiopeptide imaging and indications for it use. We also discuss the role of 18F-FDG and other tracers in the management of NETs. The second half of the article focuses on radiotargeted treatment of NETs, discussing I-131 MIBG therapy and focussing on the emergence of peptide receptor radionuclide therapy. We discuss the clinical results, toxicities and patient selection for PRRT. Key words: DOTA octreotide, DOTATATE, Ga-68, Lu-177, metaiodobenzylguanidine, neuroendocrine tumours, peptide receptor radionuclide therapy, Y-90 

scholarly journals Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Christian Maaß ◽  
Jan Philipp Sachs ◽  
Deni Hardiansyah ◽  
Felix M. Mottaghy ◽  
Peter Kletting ◽  
...  
Keyword(s):  
Treatment Planning ◽  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor ◽  
Sampling Schedule

Treatment planning algorithm for peptide receptor radionuclide therapy considering multiple tumor lesions and organs at risk

2018 ◽  
Vol 45 (8) ◽  
pp. 3516-3523 ◽  
Author(s):  
Luis David Jiménez-Franco ◽  
Peter Kletting ◽  
Ambros J. Beer ◽  
Gerhard Glatting
Keyword(s):  
At Risk ◽  
Treatment Planning ◽  
Radionuclide Therapy ◽  
Organs At Risk ◽  
Peptide Receptor Radionuclide Therapy ◽  
Multiple Tumor ◽  
Peptide Receptor ◽  
Planning Algorithm

The role of dosimetric calculations in optimizing peptide receptor radionuclide therapy by [177Lu-DOTA0, Tyr3] octreotate

2014 ◽  
Vol 30 ◽  
pp. e114-e115 ◽  
Author(s):  
Irini Baka ◽  
Maria Argyrou ◽  
Marina Michalitsi ◽  
Alexia Valassi ◽  
Agapi Ploussi ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Peptide Receptor Radionuclide Therapy ◽  
Peptide Receptor
Sign in / Sign up

Export Citation Format

Share Document